# üîí Compliance Documentation

**–ü–æ—Å–ª–µ–¥–Ω–µ–µ –æ–±–Ω–æ–≤–ª–µ–Ω–∏–µ**: 14 —Å–µ–Ω—Ç—è–±—Ä—è 2025  
**–í—Å–µ–≥–æ –¥–æ–∫—É–º–µ–Ω—Ç–æ–≤**: 7  
**–°—Ç–∞—Ç—É—Å**: –¢—Ä–µ–±—É–µ—Ç—Å—è –¥–æ—Ä–∞–±–æ—Ç–∫–∞ references

---

## üéØ **–¶–µ–ª—å**

–ù–æ—Ä–º–∞—Ç–∏–≤–Ω—ã–µ –¥–æ–∫—É–º–µ–Ω—Ç—ã –∏ —Ä—É–∫–æ–≤–æ–¥—Å—Ç–≤–∞ –¥–ª—è –æ–±–µ—Å–ø–µ—á–µ–Ω–∏—è —Å–æ–æ—Ç–≤–µ—Ç—Å—Ç–≤–∏—è GACP/GMP —Å—Ç–∞–Ω–¥–∞—Ä—Ç–∞–º –≤ ERP —Å–∏—Å—Ç–µ–º–µ. –°–ª—É–∂–∞—Ç –∏—Å—Ç–æ—á–Ω–∏–∫–æ–º —Ç—Ä–µ–±–æ–≤–∞–Ω–∏–π –¥–ª—è URS, FS, TestCases –∏ Compliance Reports.

---

## üìã **–î–æ–∫—É–º–µ–Ω—Ç—ã —Å–æ–æ—Ç–≤–µ—Ç—Å—Ç–≤–∏—è**

### ‚úÖ –ì–æ—Ç–æ–≤—ã–µ –¥–æ–∫—É–º–µ–Ω—Ç—ã

| –§–∞–π–ª          | –û–ø–∏—Å–∞–Ω–∏–µ                            | –°—Ç–∞—Ç—É—Å    | –†–∞–∑–º–µ—Ä   |
| ------------- | ----------------------------------- | --------- | -------- |
| **ALCOA+.md** | –ü—Ä–∏–Ω—Ü–∏–ø—ã —Ü–µ–ª–æ—Å—Ç–Ω–æ—Å—Ç–∏ –¥–∞–Ω–Ω—ã—Ö –¥–ª—è GxP | üü¢ Active | 98 —Å—Ç—Ä–æ–∫ |

### üî∂ –ö—Ä–∞—Ç–∫–∏–µ —Å–ø—Ä–∞–≤–æ—á–Ω–∏–∫–∏ (—Ç—Ä–µ–±—É—é—Ç –¥–æ—Ä–∞–±–æ—Ç–∫–∏)

| –§–∞–π–ª                      | –û–ø–∏—Å–∞–Ω–∏–µ                                          | –°—Ç–∞—Ç—É—Å       | –†–∞–∑–º–µ—Ä    | –ü—Ä–∏–æ—Ä–∏—Ç–µ—Ç   |
| ------------------------- | ------------------------------------------------- | ------------ | --------- | ----------- |
| **WHO_GACP.md**           | –ë–∞–∑–æ–≤—ã–µ —Ç—Ä–µ–±–æ–≤–∞–Ω–∏—è WHO –ø–æ GACP                    | üî¥ Reference | 29 —Å—Ç—Ä–æ–∫  | –í—ã—Å–æ–∫–∏–π     |
| **EMA_GACP.md**           | –ï–≤—Ä–æ–ø–µ–π—Å–∫–∏–µ —Ç—Ä–µ–±–æ–≤–∞–Ω–∏—è –¥–ª—è –º–µ–¥–∏—Ü–∏–Ω—Å–∫–æ–≥–æ –∫–∞–Ω–Ω–∞–±–∏—Å–∞ | üî¥ Reference | 20 —Å—Ç—Ä–æ–∫  | –í—ã—Å–æ–∫–∏–π     |
| **EU_GMP_Annex11.md**     | –¢—Ä–µ–±–æ–≤–∞–Ω–∏—è –∫ –∫–æ–º–ø—å—é—Ç–µ—Ä–∏–∑–∏—Ä–æ–≤–∞–Ω–Ω—ã–º —Å–∏—Å—Ç–µ–º–∞–º        | üî¥ Reference | 26 —Å—Ç—Ä–æ–∫  | –ö—Ä–∏—Ç–∏—á–µ—Å–∫–∏–π |
| **FDA_21CFR_Part11.md**   | –≠–ª–µ–∫—Ç—Ä–æ–Ω–Ω—ã–µ –∑–∞–ø–∏—Å–∏ –∏ –ø–æ–¥–ø–∏—Å–∏                      | üî¥ Reference | 25 —Å—Ç—Ä–æ–∫  | –ö—Ä–∏—Ç–∏—á–µ—Å–∫–∏–π |
| **MHRA_DataIntegrity.md** | –ö—Ä–∏—Ç–µ—Ä–∏–∏ —Ü–µ–ª–æ—Å—Ç–Ω–æ—Å—Ç–∏ –¥–∞–Ω–Ω—ã—Ö MHRA                  | üî¥ Reference | 53 —Å—Ç—Ä–æ–∫–∏ | –í—ã—Å–æ–∫–∏–π     |
| **GAMP5.md**              | –ü–æ–¥—Ö–æ–¥ –∫ —Ä–∞–∑—Ä–∞–±–æ—Ç–∫–µ –∏ –≤–∞–ª–∏–¥–∞—Ü–∏–∏ —Å–∏—Å—Ç–µ–º            | üî¥ Reference | 26 —Å—Ç—Ä–æ–∫  | –°—Ä–µ–¥–Ω–∏–π     |

---

## üîó **–ò–Ω—Ç–µ–≥—Ä–∞—Ü–∏—è —Å ERP**

### –ò—Å–ø–æ–ª—å–∑–æ–≤–∞–Ω–∏–µ –≤ –≤–∞–ª–∏–¥–∞—Ü–∏–∏:

- **URS —Ç—Ä–µ–±–æ–≤–∞–Ω–∏—è**: –ò–∑–≤–ª–µ—á–µ–Ω–∏–µ —Ñ—É–Ω–∫—Ü–∏–æ–Ω–∞–ª—å–Ω—ã—Ö —Ç—Ä–µ–±–æ–≤–∞–Ω–∏–π
- **FS —Å–ø–µ—Ü–∏—Ñ–∏–∫–∞—Ü–∏–∏**: –¢–µ—Ö–Ω–∏—á–µ—Å–∫–∞—è —Ä–µ–∞–ª–∏–∑–∞—Ü–∏—è compliance
- **TestCases**: –°—Ü–µ–Ω–∞—Ä–∏–∏ –ø—Ä–æ–≤–µ—Ä–∫–∏ —Å–æ–æ—Ç–≤–µ—Ç—Å—Ç–≤–∏—è
- **Audit Reports**: –ê–≤—Ç–æ–º–∞—Ç–∏—á–µ—Å–∫–∞—è –ø—Ä–æ–≤–µ—Ä–∫–∞ compliance

### –ú–æ–¥—É–ª–∏ ERP:

- **ComplianceModule**: –ê–≤—Ç–æ–º–∞—Ç–∏—á–µ—Å–∫–∏–π –º–æ–Ω–∏—Ç–æ—Ä–∏–Ω–≥ —Å–æ–æ—Ç–≤–µ—Ç—Å—Ç–≤–∏—è
- **AuditModule**: ALCOA+ –ø—Ä–æ–≤–µ—Ä–∫–∏ –∏ –æ—Ç—á–µ—Ç—ã
- **QMSModule**: –£–ø—Ä–∞–≤–ª–µ–Ω–∏–µ –∫–∞—á–µ—Å—Ç–≤–æ–º –ø–æ GMP
- **DataIntegrityModule**: –ö–æ–Ω—Ç—Ä–æ–ª—å —Ü–µ–ª–æ—Å—Ç–Ω–æ—Å—Ç–∏ –¥–∞–Ω–Ω—ã—Ö

---

## üìä **–ü—Ä–∏–æ—Ä–∏—Ç–µ—Ç—ã –¥–æ—Ä–∞–±–æ—Ç–∫–∏**

### Phase 1 - –ö—Ä–∏—Ç–∏—á–µ—Å–∫–∏–µ (FDA/EU GMP):

1. üî¥ **EU_GMP_Annex11.md** - –¥–µ—Ç–∞–ª—å–Ω—ã–µ —Ç—Ä–µ–±–æ–≤–∞–Ω–∏—è –∫ —Å–∏—Å—Ç–µ–º–∞–º
2. üî¥ **FDA_21CFR_Part11.md** - —ç–ª–µ–∫—Ç—Ä–æ–Ω–Ω—ã–µ –∑–∞–ø–∏—Å–∏ –∏ –ø–æ–¥–ø–∏—Å–∏
3. üî¥ **MHRA_DataIntegrity.md** - —Ä–∞—Å—à–∏—Ä–µ–Ω–Ω—ã–µ ALCOA+ –ø—Ä–∏–Ω—Ü–∏–ø—ã

### Phase 2 - GACP —Å—Ç–∞–Ω–¥–∞—Ä—Ç—ã:

1. üî∂ **WHO_GACP.md** - –±–∞–∑–æ–≤—ã–µ —Ç—Ä–µ–±–æ–≤–∞–Ω–∏—è –∫—É–ª—å—Ç–∏–≤–∞—Ü–∏–∏
2. üî∂ **EMA_GACP.md** - –µ–≤—Ä–æ–ø–µ–π—Å–∫–∏–µ –º–µ–¥–∏—Ü–∏–Ω—Å–∫–∏–µ —Ç—Ä–µ–±–æ–≤–∞–Ω–∏—è

### Phase 3 - –ú–µ—Ç–æ–¥–æ–ª–æ–≥–∏—è:

1. üî∑ **GAMP5.md** - —Ä–∞—Å—à–∏—Ä–µ–Ω–Ω–æ–µ —Ä—É–∫–æ–≤–æ–¥—Å—Ç–≤–æ –ø–æ –≤–∞–ª–∏–¥–∞—Ü–∏–∏

---

–≠—Ç–∏ –¥–æ–∫—É–º–µ–Ω—Ç—ã –∫—Ä–∏—Ç–∏—á–µ—Å–∫–∏ –≤–∞–∂–Ω—ã –¥–ª—è regulatory compliance –∏ –¥–æ–ª–∂–Ω—ã –±—ã—Ç—å —Ä–∞—Å—à–∏—Ä–µ–Ω—ã –¥–æ –ø–æ–ª–Ω–æ—Ü–µ–Ω–Ω—ã—Ö —Ä—É–∫–æ–≤–æ–¥—Å—Ç–≤ —Å –∫–æ–Ω–∫—Ä–µ—Ç–Ω—ã–º–∏ —Ç—Ä–µ–±–æ–≤–∞–Ω–∏—è–º–∏ –¥–ª—è ERP —Å–∏—Å—Ç–µ–º—ã.
